Unlisted Trajenta patents hinder early release of generics
By Kim, Jin-Gu | translator Alice Kang
23.06.28 06:00:55
가나다라
0
Generic companies file requests to invalidate or evade 8 unlisted patents in 9 months
“Even unlisted patents must be overcome for the early release of generics”
Last listed patent expires in June of next year, but unlisted patents remain an obstacle
The patent challenges made for the early release of antidiabetic ‘Trajenta (linagliptin)’ is going through a rough patch. The patents that the original company registered with KIPO but not with the MFDS are acting as obstacles.
For the generics companies that filed patent challenges, a prolonged dispute is now inevitable as they would have to overcome all of Trajenta's unlisted patents, which may be up to 10 or more, in order to release their generics.
Number of claims have been filed against Trajenta’s unlisted patents... 8 in total in 9 months
▲Pic of Trajenta
According to industry sources on the 28th, Genuone Sciences filed a trial against Boehringer Ingelheim to invalidate T
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)